Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Gotsis

Interventional Cardiology Middletown, NY Medical Doctor

NPI 1215921606 CMS profile 99882

155 Crystal Run Rd, Middletown, NY 10941

Open in the dashboard

General payments

$7,301

302 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Gotsis of Middletown, NY is reported in the CMS Open Payments database as having received $7,301 across 302 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 49th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $775 34
2024 General $1,759 71
2023 General $1,011 38
2022 General $1,048 40
2021 General $942 41
2020 General $539 26
2019 General $1,227 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Gotsis
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to William Gotsis were reported at $775. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year William Gotsis Interventional Cardiology median Middle half National median
2019 $1,227 $1,097 $329–$3,048 $163
2020 $539 $473 $161–$1,480 $114
2021 $942 $677 $233–$1,827 $132
2022 $1,048 $978 $333–$2,724 $149
2023 $1,011 $1,136 $382–$2,986 $160
2024 $1,759 $1,181 $395–$3,326 $164
2025 $775 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $1,361 65 payments
  2. Abbott Laboratories $1,272 48 payments
  3. Medtronic, Inc. $1,108 36 payments
  4. Amgen Inc. $446 21 payments
  5. Novartis Pharmaceuticals Corporation $436 16 payments
  6. AstraZeneca Pharmaceuticals LP $408 21 payments
  7. Abiomed $370 11 payments
  8. Janssen Pharmaceuticals, Inc $340 21 payments
  9. Shockwave Medical, Inc $326 6 payments
  10. KARL STORZ Endoscopy-America $148 1 payment
  11. Other $1,086 56 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,282 301 payments
  2. Education $19 1 payment
Products named General payments · program years 2019–2025
  1. Xience Sierra Coronary Stent $639 30 payments
  2. LEQVIO $436 16 payments
  3. Repatha $411 19 payments
  4. XARELTO $340 21 payments
  5. Impella $312 9 payments
  6. Abre $302 21 payments
  7. THORATEC HEARTMATE 3 LVAS IMPLANT KIT $284 2 payments
  8. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $268 4 payments
  9. LUX-Dx Insertable Cardiac Monitor $234 13 payments
  10. FARXIGA $216 7 payments
  11. Other $3,760 163 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 55 drugs

Part D claims

6,901

Median for Cardiology: 2,533

Drug cost

$1,038,461

Median for Cardiology: $485,213

Branded share of claims

27.9%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 378 $440,609
Xarelto Rivaroxaban Brand 132 $175,294
Entresto Sacubitril/Valsartan Brand 126 $151,539
Repatha Sureclick Evolocumab Brand 100 $117,502
Praluent Pen Alirocumab Brand 35 $34,772
Farxiga Dapagliflozin Propanediol Brand 29 $29,257
Ranolazine Er Ranolazine Brand 140 $14,152
Metoprolol Succinate Generic 776 $10,189
Rosuvastatin Calcium Generic 534 $7,731
Atorvastatin Calcium Generic 682 $6,985

The 10 drugs with the highest cost, of 55 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 99 billing codes

Paid by Medicare

$371,596

Of which drugs: $5,778

Medicare patients

1,095

Average age 75

Services billed

5,496

497 women, 598 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 73%
Arthritis 53%
Diabetes 42%
Heart failure 30%
Chronic kidney disease 30%
Atrial fibrillation 29%
COPD 28%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 25 25 $2,046

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $207
$207 — —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $123
$123 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $80
$80 126 —
Repatha
  • Amgen Inc. $67
$67 100 —
Inpefa
  • Lexicon Pharmaceuticals, Inc. $25
$25 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

302 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record